Gore's TAG Conformable Thoracic Stent Graft With Active Control System Introduced in Australia
July 2, 2018—Gore & Associates announced the commercial introduction in Australia of its TAG conformable thoracic stent graft with Active Control system, which was included on the Australian Register of Therapeutic Goods last month. The first commercial thoracic endovascular aortic repair (TEVAR) procedures implanting the device were performed by Professor Ian Spark, MD, at Flinders Medical Center in Adelaide, South Australia.
In Gore's announcement, Prof. Sparks commented, “The Gore TAG conformable stent graft is a reliable and trusted device that I have used for TEVAR procedures with my patients for many years. The availability of the new Gore Active Control system is an exciting advancement because it significantly enhances the control I have when deploying the stent graft, making it easier to accommodate challenging anatomies. The angulation and precision deployment capabilities could decrease the risk of common complications and reduce the likelihood for future interventions that result in additional trauma for patients and costs to providers. Both the control in the delivery system and long-term benefits of the stent graft mark significant advancement for the medical community.”
The company stated that the TAG TEVAR device, which features a new delivery system that provides controlled, staged deployment, is designed to optimize accuracy, angulation, and apposition to treat etiologies of the descending thoracic aorta including aneurysms, transections, and acute and chronic type B dissections. Gore's Active Control system enhances the stent graft's conformability, facilitating the optimized wall apposition of the conformable TAG device even in complex anatomies, such as acute aortic angles.